Notes From the Field: Severe Hand, Foot, and Mouth Disease Associated With Coxsackievirus A6—Alabama, Connecticut, California, and Nevada, November 2011–February 2012 FREE

MMWR. 2012;61:213-214

Hand, foot, and mouth disease (HFMD) is a common viral illness caused by enteroviruses that predominantly affects children aged <5 years. In the United States, outbreaks of HFMD typically occur during summer and autumn months. The most common cause of HFMD in the United States has been enterovirus serotype coxsackievirus A16. Most infections are asymptomatic; persons with signs and symptoms typically have a mild febrile illness with rash on the palms of the hands and soles of the feet, and sores in the mouth. HFMD also has been associated, often weeks after initial symptom onset, with nail dystrophies (e.g., Beau's lines or nail shedding).

From November 7, 2011, to February 29, 2012, CDC received reports of 63 persons with signs and symptoms of HFMD or with fever and atypical rash in Alabama (38 cases), California (seven), Connecticut (one), and Nevada (17). HFMD is not a reportable disease in the United States; the cases were identified as unusual by health-care providers or by a department of health that contacted CDC for diagnostic assistance. Clinical specimens were collected from patients in 34 of the 63 cases. Coxsackievirus A6 (CVA6) was detected in 25 (74%) of those 34 patients by reverse transcriptase—polymerase chain reaction and partial sequencing of the VP1 gene at CDC or at the California Department of Public Health. No enteroviruses were detected in the other nine patients.

Of the 63 patients, 40 (63%) were aged <2 years, and 15 (24%) were adults aged ≥18 years; 44 (70%) of the patients had exposure to a child care facility or school, and eight (53%) of the 15 adults had contact with children in child care where cases of HFMD were reported, or provided medical care or were related to a child with HFMD. Rash and fever were more severe, and hospitalization was more common than with typical HFMD. Signs of HFMD included fever (48 patients [76%]); rash on the hands or feet, or in the mouth (42 [67%]); and rash on the arms or legs (29 [46%]), face (26 [41%]), buttocks (22 [35%]), and trunk (12 [19%]). Of 46 patients with rash variables reported, the rash typically was maculopapular; vesicles were reported in 32 (70%) patients and scabs in 30 (65%) patients. Shedding of nails occurred after initial infection in two (4%) patients. Of the 63 patients, 51 (81%) sought care from a clinician, and 12 (19%) were hospitalized. Reasons for hospitalization varied and included dehydration and/or severe pain. No deaths were reported.

The age ranges of patients, severity of illness, seasonality of disease, and identification of CVA6 in these cases were unusual for HFMD in the United States. CVA6 has been associated with more severe and extensive rash than HFMD caused by other enteroviruses.¹ Since 2008, international outbreaks of CVA6 HFMD in children and adults have been described,^1,2,3,4 but no outbreaks had been reported in the United States previously. Although all 25 of the CVA6 strains identified in the U.S. cases were genetically closely related (based on partial VP1 gene sequences) to CVA6 strains identified in recent international outbreaks, no epidemiologic evidence (e.g., travel history) has directly linked any of the U.S. cases to importation.

HFMD is spread from person to person by contact with saliva, respiratory secretions, fluid in vesicles, and feces. Transmission of HFMD can be reduced by maintaining good hygiene, including handwashing and disinfection of surfaces in child care settings.⁵ CDC continues to receive reports of CVA6-associated HFMD. Persons who suspect a severe case of HFMD should contact their health-care provider. Local or state health departments may contact CDC for assistance with enterovirus laboratory diagnosis.

Reported by: Mary G. McIntyre, MD, Kelly M. Stevens, MS, Sherri Davidson, MPH, Tina Pippin, Dagny Magill, MPH, Alabama Dept of Health. Julie A. Kulhanjian, MD, Children's Hospital and Research Center, Oakland; Daniel Kelly, MD, Pacific Pediatrics Medical Group, San Francisco; Tara L. Greenhow, MD, Kaiser Permanente, San Francisco; Maria L. Salas, MPH, Shigeo Yagi, PhD, Tasha Padilla, Ricardo Berumen, Carol Glaser, MD, California Dept of Public Health. Marie Louise Landry, MD, Jason Lott, MD, Yale New Haven Hospital, New Haven, Connecticut. Lei Chen, PhD, Susanne Paulson, Melissa Peek, Kathleen Hanley, Randall Todd, DrPH, Joseph Iser, MD, DrPH, Washoe County Health District, Reno, Nevada. Dianna M. Blau, DVM, PhD, Div of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases; Shannon Rogers, MS, Allan Nix, Steve Oberste, PhD, Lauren J. Stockman, MPH, Eileen Schneider, MD, Div of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC. Corresponding contributor: Lauren J. Stockman, lstockman@cdc.gov, 404-639-2553.

REFERENCES

5 Available.